BioMaxima S.A. (WSE: BMX)
Poland
· Delayed Price · Currency is PLN 14.10
0.00 (0.00%)
Nov 20, 2024, 5:00 PM CET
BioMaxima Revenue
BioMaxima had revenue of 12.46M PLN in the quarter ending June 30, 2024, with 16.15% growth. This brings the company's revenue in the last twelve months to 48.97M, up 1.61% year-over-year. In the year 2023, BioMaxima had annual revenue of 46.79M, down -67.48%.
Revenue (ttm)
48.97M
Revenue Growth
+1.61%
P/S Ratio
1.22
Revenue / Employee
425.86K
Employees
115
Market Cap
59.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 46.79M | -97.08M | -67.48% |
| Dec 31, 2022 | 143.87M | 64.78M | 81.91% |
| Dec 31, 2021 | 79.09M | 17.81M | 29.06% |
| Dec 31, 2020 | 61.28M | 30.67M | 100.19% |
| Dec 31, 2019 | 30.61M | -1.41M | -4.40% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Krka, d. d. | 8.14B |
| NEUCA S.A. | 12.13B |
| Sopharma AD | 4.35B |
| Synektik Spólka Akcyjna | 618.67M |
| Celon Pharma S.A. | 206.81M |
| Voxel S.A. | 476.19M |
| Ryvu Therapeutics S.A. | 91.18M |
| Selvita S.A. | 329.02M |